-

insitro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Company Leaders to Participate in Multiple Industry Forums Throughout Healthcare Week

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced that Daphne Koller, Ph.D., founder and CEO, will present a company update, including its AI-enabled discovery engine and therapeutic candidates advancing to the clinic, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, at 4:00 p.m. PT in San Francisco.

Additional insitro participation at healthcare week events:

  • Longwood Healthcare Leaders’ San Francisco CEO Conference
    Daphne Koller, Ph.D., will participate on the panel "Identifying Next-Generation Therapeutics" on Sunday, Jan. 11, at 1:30 p.m. PT
  • KPMG + Goodwin Symposium
    Mary Rozenman, Ph.D., CFO and CBO, will join the panel "Transaction to Transformation: Innovative End-to-End Strategies for Life Sciences Companies Amid Market Volatility" on Wednesday, Jan. 14, at 11:30 a.m. PT.

insitro's J.P. Morgan presentation will be made available on the insitro website following the event.

About insitro

insitro is the AI therapeutics company built on causal biology. By generating an integrated, multimodal corpus of human and cellular data and analyzing it with machine learning, insitro’s platform aims to reveal how disease begins, progresses, and can be resolved. The company applies this approach to identify genetic drivers, prioritize targets, and design medicines intended to treat disease at its root, with programs focused in metabolic disease and neuroscience. insitro is backed by world-class investors and has raised approximately $800M in capital, including approximately $150M from non-dilutive pharma partnerships.

Contacts

Media contact
Eric McKeeby
eric@insitro.com

Industry:

insitro

Release Versions
English

Contacts

Media contact
Eric McKeeby
eric@insitro.com

More News From insitro

insitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the publication of research in Nature Communications validating its POSH (Pooled Optical Screening in Human cells) platform. The study details the development of CellPaint-POSH, a scalable approach that integrates pooled CRISPR screening, high-content imaging, and advanced machine learning to map gene function at scale without relying on predefined biomarkers or human-engi...

insitro Appoints R&D Veteran Stephen Hitchcock and AI Visionary Vijay Pande as Scientific Advisors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the appointment of two scientific advisors: Stephen Hitchcock, Ph.D., a preeminent drug development leader and former Chief Scientific Officer of Takeda, and Vijay Pande, Ph.D., co-founder of VZVC and, previously, founder and General Partner of Andreessen Horowitz's Bio + Health fund. Hitchcock and Pande will advise on the continued development and scaling of insitro's AI-...

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a pioneer in machine learning–driven drug discovery and development, and Bristol Myers Squibb (NYSE: BMY), today announced the next phase of their collaboration to discover new molecules with potential as new treatments for amyotrophic lateral sclerosis (ALS). The collaboration extension will leverage insitro’s AI-enabled ChemML™ platform to design new medicines for a novel ALS target that was identified in the first biological evaluation p...
Back to Newsroom